.jpeg)
Most clinical trial recruitment has a quiet flaw: it only reaches patients who already know what to look for. Ads target precise keywords; sites target existing foot traffic.
But most eligible patients aren’t searching for trials. They’re searching for answers about symptoms, diagnoses, and options. They don't know a trial is even on the table.
Reaching them requires a multichannel approach because patient journeys aren't one-size-fits-all. One patient acts on a search ad. Another waits for a physician referral. A third only trusts their local advocacy group. Often, it’s the repetition across these channels that finally builds the confidence to enroll.
That is the real value of omnipresent outreach. A patient who isn't ready to act in June might finally be ready by December, but only if you've stayed present in their community.
Single-channel recruitment misses a large share of eligible patients for one simple reason: no two patients are reached the same way. Around 80% of trials fall short of their enrollment timelines, even as digital ad spend keeps climbing. More budget in one channel does not solve that, because the problem is reach, not volume.
Picture two eligible patients for the same study. One finds it in a Facebook group at midnight. The other hears about it from their rheumatologist at a routine visit. Same trial, two completely different paths in. Reach only one channel, and you reach only one of them.
Targeted paid campaigns run across Google, Facebook, Instagram, and Reddit, along with health-focused advertising networks built specifically for patient recruitment, such as ClinicalTrialMedia and GoodLabs. Campaigns are geo-targeted to reach patients within a set radius of research sites, then adjusted regularly based on performance data.
Why it matters: Paid advertising captures patients who are actively looking for answers about their condition. It is a high-intent audience that converts well when the message is right, and health-specific platforms extend that reach into places general ad networks cannot.
PatientWing builds condition-specific pages with educational content on the disease, treatment options, and trial opportunities. Patient stories, written from real patient perspectives, are published and often reshared organically within patients' own communities.
Why it matters: SEO-driven content reaches patients through organic search, with no ad spend required. And patient stories build trust in a way no advertisement can. When a patient reads someone else's experience, they see themselves in it.
PatientWing partners with patient advocacy organizations to share study information, run awareness campaigns, and reach patients through networks that already hold the community's trust.
Why it matters: Advocacy groups have built relationships that take years to develop. Partnering with them means entering a community through a trusted door instead of a cold one.
PatientWing engages directly with patients in patient-run Facebook groups, Instagram communities, Reddit forums, and online support groups. It also shows up in podcasts, patient-run blogs and websites, and other spaces where specific communities gather. Offline, that extends to health fairs, churches, libraries, academic institutions, HBCUs, and community centers, plus local businesses and community influencers who already have credibility. The channels are chosen condition by condition, based on where those particular patients actually build community.
Why it matters: This is where underrepresented and underdiagnosed patients actually are. They are not browsing clinical trial websites. They are in their communities, and that is where PatientWing meets them.
Study materials are translated into the languages patients actually speak. PatientWing employs team members across the globe who speak a range of languages, and partners with certified translation providers when a language is not covered in house. Imagery, language, and FAQs are chosen to resonate with specific communities, and patient advocates are trained in cultural sensitivity.
Why it matters: A campaign that only exists in English will only reach English-speaking patients. Trials also run across many countries, each with its own languages and cultural norms, so outreach has to adapt to every market a study operates in. For conditions that disproportionately affect non-English-speaking communities, this is not optional.
When patients go quiet, PatientWing does not move on. Proactive check-ins by phone, text, and email keep patients in the pipeline. IRB-approved materials, including patient stories, condition articles, and study updates, are shared to maintain engagement over long timelines.
Why it matters: Most recruitment campaigns end at the referral. PatientWing's outreach continues through the full enrollment journey, because a patient who goes quiet is often a patient who just needs more time and a different kind of follow-up.
Every study PatientWing supports gets a dedicated, patient-friendly study website with an online pre-screener. Patients get a clear, accessible place to learn about the study and self-qualify, in their own time, from their own home.
Why it matters: For someone managing a serious condition, the barrier to engagement needs to be as low as possible. A simple website with plain language and an easy pre-screener removes friction at the most critical moment, first contact.
PatientWing keeps in regular contact with patient communities through newsletter updates, sharing condition-relevant content, study updates, and resources between other outreach touchpoints.
Why it matters: Not every patient is ready to act when they first hear about a study. A steady newsletter keeps them informed and engaged, so PatientWing is already a familiar name when the timing is finally right.
When every channel works together, digital advertising, community relationships, advocacy partnerships, culturally adapted materials, and ongoing patient support, enrollment does not just reach more patients. It reaches the right ones. And it keeps them.
PatientWing was built on a simple belief: every patient deserves to know that clinical research is an option for them. Multichannel outreach is how we turn that belief into a strategy that actually delivers. If you're ready to reach the patients others miss, explore our solutions or contact us today to jumpstart your trial's enrollment.
